RESUMO
1. Plasma levels were monitored for about 18 months during therapy with haloperidol decanoate. When steady-state was reached, patients treated without enzyme inducers showed in their plasma concentrations a stable plateau and a very low fluctuation. Furthermore, doses were correlated to plasma levels (r = 0.9). 2. Contrary, patients treated with both haloperidol decanoate and enzyme inducers seemed to present in their plasma concentration a very large fluctuation with C min (plasma concentrations measured just before the injection) significantly lower than those of the other group. Moreover their C min values were excluded from the linear regression curve calculated between plasma levels and doses in patients without enzyme inducers. 3. Our data suggest a shortening of the absorption half-time of haloperidol. In this case, it seems necessary to diminish the interval between injections than to give higher dosage in order to maintain plasma concentrations.
Assuntos
Antipsicóticos/sangue , Carbamazepina/farmacologia , Haloperidol/análogos & derivados , Fenobarbital/farmacologia , Esquizofrenia/tratamento farmacológico , Antipsicóticos/farmacocinética , Antipsicóticos/uso terapêutico , Relação Dose-Resposta a Droga , Interações Medicamentosas , Haloperidol/sangue , Haloperidol/farmacocinética , Haloperidol/uso terapêutico , Humanos , Esquizofrenia/sangueRESUMO
Plasma levels of 3-methoxy-4-hydroxyphenylglycol (MHPG) were found to be significantly higher in manic patients than in age- and sex-matched normal controls (n = 22). In 18 manic patients plasma MHPG correlated with manic symptoms but not with anxiety, depression, motor behaviour, acute psychosis, schizophrenia and severity of illness. A positive correlation between MHPG and grandiosity items on rating scales suggests a link with cognitive contents and therefore a relationship with central factors.
